Active Pharmaceutical Ingredients/API Market

Active Pharmaceutical Ingredients/API Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone) Drug (OTC, Rx), Therapy (Diabetes, Oncology, CNS, CVD) - Global Forecast to 2021

Report Code: PH 1262 Jan, 2017, by marketsandmarkets.com

[312 Pages Report] The global active pharmaceutical ingredients market is expected to reach USD 213.97 billion by 2021 from USD 157.95 billion in 2016, growing at a CAGR of 6.3% from 2016 to 2021. The factors driving market growth include increasing incidence of chronic diseases, rising prevalence of cancer, technological advancements in API manufacturing, growing importance of generics, rapidly increasing geriatric population, increase in abbreviated new drug applications (ANDA) and increasing uptake of biopharmaceuticals. However, factors such as stringent regulatory requirements and unfavorable drug price control policies across various countries may restrain the market growth.

Market Dynamics

Drivers

  • Increasing incidence of chronic diseases
  • Rising prevalence of cancer
  • Technological advancements in API manufacturing
  • Growing importance of generics
  • Rapidly increasing geriatric population
  • Increase in Abbreviated New Drug Applications (ANDA)
  • Increasing uptake of biopharmaceuticals

Restraints

  • Stringent regulatory requirements
  • Unfavorable drug price control policies across various countries

Opportunities

  • Emerging biosimilars market
  • Increasing scope for HPAPIs
  • Emerging markets
  • Emerging technologies

Challenges

  • Product differentiation
  • Higher manufacturing costs

Increasing uptake of biopharmaceuticals are the major driver for the market

Biopharmaceuticals are gradually becoming popular in the healthcare industry as they are similar to natural biological compounds found in the human body, and thus offer high efficacy and fewer side effects. Moreover, continued research in the field of biologics is triggering the development of novel innovative products. Novel concepts like cell therapy (for the treatment of cancer) and gene therapy (offering regenerative medicine) are getting refined. This presents biopharmaceuticals as a huge and attractive opportunity pocket in the active pharmaceutical ingredients market.

Currently, biopharmaceuticals form the fastest-growing segment in the pharmaceuticals industry. The growth rate of this segment is expected to double in the coming decade. The efficacy and safety associated with biopharmaceutical products, combined with their ability to address previously untreatable conditions, allows pharmaceutical companies to command high prices for innovative drugs, thus contributing significantly to their overall revenue. Majority of the blockbuster drugs currently available in the market are biopharmaceuticals—among the top 15 biopharma products, each enjoys an annual revenue of more than USD 2 billion. Humira [AbbVie Inc. (U.S.)] has consistently remained the number one blockbuster drug (in terms of sales) in the U.S., with sales of USD 12,543 million and USD 14,012 million in 2014 and 2015, respectively. Hence, major pharmaceutical companies across the globe are increasingly shifting their R&D and sourcing to focus on the development of large-molecule products. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), in 2015, the total R&D investment of PhRMA member companies amounted to approximately USD 58.8 billion, representing majority of biopharmaceutical R&D spending in the U.S. Moreover, the biopharmaceuticals sector accounts for the single largest share (~17%) of R&D spending by U.S. businesses. Growing investments in biotech R&D have resulted in a strong biologic-development pipeline, which is expected to support the healthy and continued growth of this segment.

The following are the major objectives of the study.

  • To define, describe, and forecast the global APIs market on the basis of type, type of manufacturer, type of synthesis, type of drug, therapeutic application, and region
  • To provide detailed information regarding the major factors influencing growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
  • To strategically analyze micromarkets1 with respect to the individual growth trends, future prospects, and contributions to the overall market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia, and the Rest of the World (RoW)2
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies3
  • To track and analyze competitive developments such as partnerships, agreements, collaborations, joint ventures, alliances, mergers & acquisitions, approvals, expansions, and R&D activities in the global APIs market

During this research study, major players operating in the APIs market in various regions have been identified, and their offerings, regional presence, and distribution channels have been analyzed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Factiva, along with primary respondents. The entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) pertaining to the market. The figure below shows the breakdown of the primaries on the basis of the company type, designation, and region considered during the research study.

To know about the assumptions considered for the study, download the pdf brochure

The APIs market is competitive in nature, with several major players competing for market space. Some of the prominent players in the market include Pfizer Inc. (U.S.), Novartis International AG (Switzerland), Merck & Co. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Mylan, Inc. (U.S.), Boehringer Ingelheim (Germany), Sanofi (France), AbbVie (U.S.), Eli Lilly and Company (U.S.), AstraZeneca plc (U.K.), Bristol-Myers Squibb (U.S.), and GlaxoSmithKline plc (U.K.).

Major Market Developments

  • In August 2016 , Pfizer entered into an agreement with AstraZeneca (U.K.) to acquire the development and commercialization rights of its small molecule anti-infectives business, primarily outside the United States.
  • In June 2016, Novartis entered into a collaboration and licensing agreement with Xencor (U.S.), a biopharmaceutical company that develops engineered monoclonal antibodies. The purpose of this agreement was to develop bispecific antibodies for treating cancer.
  • In February 2016, Sandoz acquired from Pfizer the rights for the development and commercialization of PF-06438179 (biosimilar infliximab) in the 28 countries that form the European Economic Area (EEA). This acquisition enables Novartis to broaden its immunology portfolio.

Market Audience:

  • Medical image management software providers
  • Diagnostic imaging equipment vendors/service providers
  • Standalone image management software/workstation providers
  • Healthcare IT service providers
  • Research and consulting firms
  • Diagnostic imaging centers
  • Hospitals
  • Venture capitalists
  • Government agencies
  • Market research and consulting firms

Report Scope

APIs Market, by Type

  • Innovative APIs
  • Generic APIS

APIs Market, by Type of Manufacturer

  • Captive Manufacturers
  • Merchant Manufacturers
    • l Merchant Manufacturers Market, by Type
    • Innovative Merchant API Manufacturers
    • Generic Merchant API Manufacturers
    • l  Merchant Manufacturers Market, by Type of Synthesis
    • Synthetic APIs
    • Biotech APIs

APIs market, by Type of Synthesis

  • Synthetic APIs Market
    • l Synthetic APIs Market, by Type
    • Innovative Synthetic APIs
    • Generic Synthetic APIs
  • Biotech APIs Market
    • l Biotech APIs Market, by Type
    • Innovative Biotech APIs
    • Biosimilars
    • l Biotech APIs Market, by Product
    • Monoclonal Antibodies
    • Hormones
    • Cytokines
    • Fusion Proteins
    • Therapeutic Enzymes
    • Vaccines
    • Blood Factors
    • l Biotech APIs Market, by Expression System
    • Mammalian Expression Systems
    • Microbial Expression Systems
    • Yeast Expression Systems
    • Insect Expression Systems
    • Plant Expression Systems
    • Other Expression Systems

APIs Market, by Type of Drug

  • Prescription Drugs
  • Over-the-counter Drugs

APIs Market, by Therapeutic Application

  • Oncology
  • Diabetes
  • Cardiovascular Disease
  • CNS and Neurological Disorders
  • Endocrinology
  • Other Therapeutic Applications (Orthopedics, Urology and Nephrology, Ophthalmology, Pulmonology, Women’s Health, and Gastroenterology)

API Market, by Region

  • North America
    • l U.S.
    • l Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia
    • Japan
    • China
    • India
    • South Korea
    • Rest of Asia (RoA)
  • Rest of the World (RoW)

    Critical questions which the report answers

    • Stringent regulatory requirements and unfavorable drug price control policies across various countries is a major concern in the industry, when will this scenario ease out?
    • Emerging countries have immense opportunities for the growth of API manufacturers, will this scenario continue?

    Available customizations

    With the given market data, MarketsandMarkets offers customizations as per the company‘s specific needs.
    The following customization options are available for the report:

    Company Information

    • Detailed analysis and profiling of additional market players (Up to 5)

    Geographic Analysis

    • Further breakdown of the Rest of the World medical imaging management market into Pacific countries, the Middle East and Africa (MEA), and Latin America (LATAM)

    Innovative APIs to grow at the highest CAGR during the forecast period.

    Based on type, the APIs market is segmented into innovative and generic APIs. The innovative APIs segment is expected to account for the largest share in 2016. The large share of this segment can be attributed to the increasing number of FDA approvals for new molecular entities, higher price commanded by innovative APIs as compared to their generic equivalents, and growing focus of innovator APIs companies on R&D for the development of novel innovative APIs products to cater to the previously unmet medical needs of the market.

    The global active pharmaceutical ingredients market is expected to reach USD 213.97 billion by 2021 from USD 157.95 billion in 2016, growing at a CAGR of 6.3% from 2016 to 2021. Market growth is driven by the increasing incidence of chronic diseases, rising prevalence of cancer, technological advancements in API manufacturing, growing importance of generics, rapidly increasing geriatric population, increase in abbreviated new drug applications (ANDA) and increasing uptake of biopharmaceuticals. Furthermore, emerging biosimilars market, increasing scope for HPAPIs, emerging markets and emerging technologies have opened an array of opportunities for the growth of the active pharmaceutical ingredients market. However, factors such as stringent regulatory requirements and unfavourable drug price control policies across various countries may restrain the growth of this market.

    Increasing uptake of biopharmaceuticals are the major driver for the market.

    Biopharmaceuticals are gradually becoming popular in the healthcare industry as they are similar to natural biological compounds found in the human body, and thus offer high efficacy and fewer side effects. Moreover, continued research in the field of biologics is triggering the development of novel innovative products. Novel concepts like cell therapy (for the treatment of cancer) and gene therapy (offering regenerative medicine) are getting refined. This presents biopharmaceuticals as a huge and attractive opportunity pocket in the active pharmaceutical ingredients market.

    Currently, biopharmaceuticals form the fastest-growing segment in the pharmaceuticals industry. The growth rate of this segment is expected to double in the coming decade. The efficacy and safety associated with biopharmaceutical products, combined with their ability to address previously untreatable conditions, allows pharmaceutical companies to command high prices for innovative drugs, thus contributing significantly to their overall revenue. Majority of the blockbuster drugs currently available in the market are biopharmaceuticals—among the top 15 biopharma products, each enjoys an annual revenue of more than USD 2 billion. Humira [AbbVie Inc. (U.S.)] has consistently remained the number one blockbuster drug (in terms of sales) in the U.S., with sales of USD 12,543 million and USD 14,012 million in 2014 and 2015, respectively. Hence, major pharmaceutical companies across the globe are increasingly shifting their R&D and sourcing to focus on the development of large-molecule products. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), in 2015, the total R&D investment of PhRMA member companies amounted to approximately USD 58.8 billion, representing majority of biopharmaceutical R&D spending in the U.S. Moreover, the biopharmaceuticals sector accounts for the single largest share (~17%) of R&D spending by U.S. businesses. Growing investments in biotech R&D have resulted in a strong biologic-development pipeline, which is expected to support the healthy and continued growth of this segment.

    However, stringent regulatory requirements and unfavourable drug price control policies across various countries are restraining the market growth.

    Market Dynamics

    Oncology settings form the fastest growing therapeutic application segment.

    Oncology

    Oncology is the largest and the fastest-growing therapeutic application segment in the global APIs market. The large share of this segment can be attributed to the growing incidence and prevalence of cancer across the globe. According to GLOBOCAN 2012, there were 14.1 million new cancer cases, 8.2 million cancer deaths, and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012, worldwide.

    Cardiovascular disease (CVD)

    Cardiovascular disease (CVD) is a leading cause of deaths worldwide. It comprises a range of conditions, including hypertension, dyslipidemia, stroke, atherosclerosis, thrombosis, coronary heart disease, cerebrovascular disease, and rheumatic heart disease.

    Diabetes

    Diabetes is one of the leading causes of death worldwide and has almost reached epidemic proportions in many countries across the globe. According to the WHO, diabetes is expected to become the seventh-leading cause of death globally, by 2030. In 2014, the global prevalence of diabetes was estimated to be 8.5% among adults aged 18+ years. Moreover, there has been a significant rise in the prevalence of type 2 diabetes in children and adolescents.

    Central Nervous System and Neurological Disorders

    Central Nervous System (CNS) and neurological disorders affect the brain and the central and autonomic nervous systems. Neurological disorders can be categorized into central nervous system disorders and peripheral nervous system disorders. According to the WHO, approximately 350 million people globally suffered from depression in 2012.

    Endocrinology

    Endocrinology therapeutics comprises drugs used for the treatment of disorders of the endocrine system, which include diseases associated with insufficient hormone supply and dysfunctional glands. These diseases include Addison’s disease, gigantism, goiter, Cushing’s syndrome, polycystic ovary syndrome (PCOS), diabetes, hypertension, hyperlipidemia, acromegaly, thyroiditis, and osteomalacia.

    Other Therapeutic Applications

    This segment includes orthopedics, urology and nephrology, ophthalmology, pulmonology, women’s health, and gastroenterology.

    Key questions

    • Stringent regulatory requirements and unfavorable drug price control policies across various countries is a major concern in the industry, when will this scenario ease out?
    • Emerging countries have immense opportunities for the growth of API manufacturers, will this scenario continue?
    • Most of the manufacturers have opted agreements, collaborations, partnerships, joint ventures, and alliances as the key strategies as could be seen from the recent developments. Where will it take the industry in the mid to long term?

    The global active pharmaceutical ingredients market is expected to reach USD 213.97 billion by 2021 from USD 157.95 billion in 2016, growing at a CAGR of 6.3% from 2016 to 2021. The active pharmaceutical ingredients market is segmented on the basis type, type of manufacturer, type of synthesis, type of drug, therapeutic application, and region. 

    Market growth is driven by the increasing incidence of chronic diseases, rising prevalence of cancer, technological advancements in API manufacturing, growing importance of generics, rapidly increasing geriatric population, increase in abbreviated new drug applications (ANDA) and increasing uptake of biopharmaceuticals. Furthermore, emerging biosimilars market, increasing scope for HPAPIs, emerging markets and emerging technologies have opened an array of opportunities for the growth of the active pharmaceutical ingredients market. However, factors such as stringent regulatory requirements and unfavorable drug price control policies across various countries may restrain the growth of this market.

    Based on type, the APIs market is segmented into innovative and generic APIs. The innovative APIs segment is expected to account for the largest share in 2016. The large share of this segment can be attributed to the increasing number of FDA approvals for new molecular entities, higher price commanded by innovative APIs as compared to their generic equivalents, and growing focus of innovator APIs companies on R&D for the development of novel innovative APIs products to cater to the previously unmet medical needs of the market.

    On the basis of type of manufacturer, the APIs market is segmented into captive and merchant manufacturers. The captive manufacturers segment is estimated to account for the largest share in 2016. The large share of this segment can be can be attributed to the growing preference of companies to maintain in-house manufacturing of innovative APIs for their economic benefits.

    On the basis of type of synthesis the, the APIs market is categorized into synthetic and biotech APIs. The synthetic APIs segment is estimated to command the largest in 2016. The emergence of new molecules in the market, increasing number of new product approvals, and technological advancements in the method of synthesis are major factors contributing to the growth of the synthetic APIs segment. However, the biotech APIs segment is expected to grow at the highest CAGR in the forecast period.

    The APIs market, on the basis of type of drug, is segmented into prescription drugs and over-the-counter (OTC) drugs.  In 2016, the prescription drugs segment is estimated to account for the largest share of the APIs market. The large share of this segment can primarily be attributed to the increasing demand for these drugs owing to the growing incidence of diseases such as cancer, cardiovascular disease, and respiratory disorders.

    The APIs market, on the basis of therapeutic applications, is segmented into oncology, cardiovascular diseases, diabetes, endocrinology, central nervous system (CNS) and neurological disorders, and other therapeutic applications. The oncology segment is estimated to account for the largest of the global active pharmaceutical ingredients market in 2016. The large share of this segment can be attributed to the increasing incidence and prevalence of cancer globally, growing focus of pharmaceutical companies for the development of novel products for cancer treatment, and growing investments in the research activities for the development of novel therapies like targeted therapies which utilize anti-body drug conjugates for the treatment of cancer. 

    The global active pharmaceutical ingredients market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). North America will continue to lead the global active pharmaceutical ingredients market in the forecast period. Over the next five years, Asia Is expected to register highest growth rate. 

    Oncology settings form the fastest growing therapeutic application segment in API market

    Oncology

    Oncology is the largest and the fastest-growing therapeutic application segment in the global APIs market. The large share of this segment can be attributed to the growing incidence and prevalence of cancer across the globe. According to GLOBOCAN 2012, there were 14.1 million new cancer cases, 8.2 million cancer deaths, and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012, worldwide.

    Cardiovascular disease (CVD)

    Cardiovascular disease (CVD) is a leading cause of deaths worldwide. It comprises a range of conditions, including hypertension, dyslipidemia, stroke, atherosclerosis, thrombosis, coronary heart disease, cerebrovascular disease, and rheumatic heart disease.

    Diabetes

    Diabetes is one of the leading causes of death worldwide and has almost reached epidemic proportions in many countries across the globe. According to the WHO, diabetes is expected to become the seventh-leading cause of death globally, by 2030. In 2014, the global prevalence of diabetes was estimated to be 8.5% among adults aged 18+ years. Moreover, there has been a significant rise in the prevalence of type 2 diabetes in children and adolescents.

    Central Nervous System and Neurological Disorders

    Central Nervous System (CNS) and neurological disorders affect the brain and the central and autonomic nervous systems. Neurological disorders can be categorized into central nervous system disorders and peripheral nervous system disorders. According to the WHO, approximately 350 million people globally suffered from depression in 2012.

    Endocrinology

    Endocrinology therapeutics comprises drugs used for the treatment of disorders of the endocrine system, which include diseases associated with insufficient hormone supply and dysfunctional glands. These diseases include Addison’s disease, gigantism, goiter, Cushing’s syndrome, polycystic ovary syndrome (PCOS), diabetes, hypertension, hyperlipidemia, acromegaly, thyroiditis, and osteomalacia.

    Other Therapeutic Applications

    This segment includes orthopedics, urology and nephrology, ophthalmology, pulmonology, women’s health, and gastroenterology.

    Critical questions the report answers:

    • Where will all these developments take the industry in the mid to long term?
    • Emerging countries have immense opportunities for the growth of API manufacturers, will this scenario continue?

    The stringent regulatory requirements and unfavorable drug price control policies across various countries are major factors restraining the growth of the market.

    Some of the prominent players in the market include Pfizer Inc. (U.S.), Novartis International AG (Switzerland), Merck & Co. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Mylan, Inc. (U.S.), Boehringer Ingelheim (Germany), Sanofi (France), AbbVie (U.S.), Eli Lilly and Company (U.S.), AstraZeneca plc (U.K.), Bristol-Myers Squibb (U.S.), and GlaxoSmithKline plc (U.K.). These players are increasingly undertaking agreements, collaborations, partnerships, joint ventures, and alliances to maintain its position in the market.

    To speak to our analyst for a discussion on the above findings, click Speak to Analyst

  • Table of Contents

    1 Introduction (Page No. - 28)
        1.1 Objectives of the Study
        1.2 Market Definition
        1.3 Study Scope
               1.3.1 Markets Covered
               1.3.2 Years Considered for the Study
        1.4 Currency
        1.5 Limitations
        1.6 Market Stakeholders

    2 Research Methodology (Page No. - 32)
        2.1 Market Size Estimation
        2.2 Market Breakdown and Data Triangulation
        2.3 Key Data From Secondary Sources
        2.4 Key Data From Primary Sources
        2.5 Key Industry Insights
        2.6 Assumptions for the Study

    3 Executive Summary (Page No. - 41)

    4 Premium Insights (Page No. - 47)
        4.1 Active Pharmaceutical Ingredients Market Overview
        4.2 Active Pharmaceutical Ingredients Market, By Type of Manufacturer
        4.3 Active Pharmaceutical Ingredients Market, By Therapeutic Area
        4.4 Biotech Active Pharmaceutical Ingredients Market, By Product
        4.5 Active Pharmaceutical Ingredients Market, By Type of Drug
        4.6 Active Pharmaceutical Ingredients Market: Geographic Snapshot

    5 Market Overview (Page No. - 52)
        5.1 Introduction
        5.2 Market Dynamics
               5.2.1 Drivers
                        5.2.1.1 Increasing Incidence of Chronic Diseases
                        5.2.1.2 Rising Prevalence of Cancer
                        5.2.1.3 Technological Advancements in API Manufacturing
                        5.2.1.4 Growing Importance of Generics
                        5.2.1.5 Rapidly Increasing Geriatric Population
                        5.2.1.6 Increase in Abbreviated New Drug Applications (ANDA)
                        5.2.1.7 Increasing Uptake of Biopharmaceuticals
               5.2.2 Restraints
                        5.2.2.1 Stringent Regulatory Requirements
                        5.2.2.2 Unfavorable Drug Price Control Policies Across Various Countries
               5.2.3 Opportunities
                        5.2.3.1 Emerging Biosimilars Market
                        5.2.3.2 Increasing Scope for High-Potency Active Pharmaceutical Ingredients
                        5.2.3.3 Emerging Markets
                        5.2.3.4 Emerging Technologies
               5.2.4 Challenges
                        5.2.4.1 Product Differentiation
                        5.2.4.2 High Manufacturing Costs

    6 Active Pharmaceutical Ingredients Market, By Type (Page No. - 64)
        6.1 Introduction
        6.2 Innovative Active Pharmaceutical Ingredients
        6.3 Generic Active Pharmaceutical Ingredients

    7 Active Pharmaceutical Ingredients Market, By Type of Manufacturer (Page No. - 73)
        7.1 Introduction
        7.2 Captive Manufacturers
        7.3 Merchant API Manufacturers
               7.3.1 Merchant Manufacturers Market, By Type
                        7.3.1.1 Innovative Merchant API Manufacturers
                        7.3.1.2 Generic Merchant API Manufacturers
               7.3.2 Merchant API Manufacturers Market, By Mode of Synthesis
                        7.3.2.1 Synthetic APIs
                        7.3.2.2 Biotech APIs

    8 Active Pharmaceutical Ingredients Market, By Type of Synthesis (Page No. - 92)
        8.1 Introduction
        8.2 Synthetic Active Pharmaceutical Ingredients
               8.2.1 Synthetic Active Pharmaceutical Ingredients Market, By Type
                        8.2.1.1 Innovative Synthetic APIs
                        8.2.1.2 Generic Synthetic APIs
        8.3 Biotech Active Pharmaceutical Ingredients
               8.3.1 Biotech Active Pharmaceutical Ingredients Market, By Type
                        8.3.1.1 Innovative Biotech APIs
                        8.3.1.2 Biosimilars
               8.3.2 Biotech Active Pharmaceutical Ingredients Market, By Product
                        8.3.2.1 Monoclonal Antibodies
                        8.3.2.2 Vaccines
                        8.3.2.3 Hormones and Growth Factors
                        8.3.2.4 Cytokines
                        8.3.2.5 Fusion Proteins
                        8.3.2.6 Therapeutic Enzymes
                        8.3.2.7 Blood Factors
               8.3.3 Biotech Active Pharmaceutical Ingredients Market, By Expression System
                        8.3.3.1 Mammalian Expression Systems
                        8.3.3.2 Microbial Expression Systems
                        8.3.3.3 Yeast Expression Systems
                        8.3.3.4 Plant Expression Systems
                        8.3.3.5 Insect Expression Systems

    9 Active Pharmaceutical Ingredients Market, By Type of Drug (Page No. - 138)
        9.1 Introduction
        9.2 Prescription Drugs
        9.3 Over-The-Counter Drugs
        9.4 Active Pharmaceutical Ingredients Market, By Potency
               9.4.1 Low to Moderate Potency Active Pharmaceutical Ingredients
               9.4.2 Potent to Highly Potent Active Pharmaceutical Ingredients

    10 Active Pharmaceutical Ingredients Market, By Therapeutic Application (Page No. - 148)
         10.1 Introduction
         10.2 Oncology
         10.3 Cardiovascular Disease
         10.4 Diabetes
         10.5 Central Nervous System and Neurological Disorders
         10.6 Endocrinology
         10.7 Other Therapeutic Applications

    11 Active Pharmaceutical Ingredients Market, By Region (Page No. - 166)
         11.1 Introduction
         11.2 North America
                 11.2.1 U.S.
                 11.2.2 Canada
         11.3 Europe
                 11.3.1 Germany
                 11.3.2 France
                 11.3.3 U.K.
                 11.3.4 Italy
                 11.3.5 Spain
                 11.3.6 Rest of Europe (RoE)
         11.4 Asia
                 11.4.1 Japan
                 11.4.2 China
                 11.4.3 India
                 11.4.4 South Korea
                 11.4.5 Rest of Asia (RoA)
         11.5 Rest of the World (RoW)

    12 Competitive Landscape (Page No. - 262)
         12.1 Overview
         12.2 Market Player Ranking
         12.3 Competitive Situation and Trends
                 12.3.1 Agreements, Collaborations, Partnerships, Joint Ventures, and Alliances
                 12.3.2 Regulatory Approvals
                 12.3.3 Mergers and Acquisitions
                 12.3.4 Expansions
                 12.3.5 Investments

    13 Company Profiles (Page No. - 270)
    (Overview, Financials, Products & Services, Strategy, and Developments)*
         13.1 Introduction
         13.2 Pfizer, Inc.
         13.3 Novartis International AG
         13.4 Sanofi
         13.5 Boehringer Ingelheim
         13.6 Bristol-Myers Squibb
         13.7 Teva Pharmaceutical Industries Ltd.
         13.8 ELI Lilly and Company
         13.9 Glaxosmithkline PLC
         13.10 Merck & Co., Inc.
         13.11 Abbvie Inc.

    *Details on Overview, Financials, Product & Services, Strategy, and Developments Might Not Be Captured in Case of Unlisted Companies.

    14 Appendix (Page No. - 296)
         14.1 Insights From Industry Experts
         14.2 Discussion Guide
         14.3 Other Developments
         14.4 Introducing RT: Real-Time Market Intelligence
         14.5 Knowledge Store: Marketsandmarkets’ Subscription Portal
         14.6 Available Customizations
         14.7 Related Reports
         14.8 Author Details


    List of Tables (369 Tables)

    Table 1 Indicative List of Generic Drugs That Gained Approval in 2016
    Table 2 Statistics on Aging Population
    Table 3 Indicative List of Biologics That Gained U.S. Regulatory Approval in 2015–2016
    Table 4 Increasing Incidence of Chronic Diseases: A Major Market Driver
    Table 5 Stringent Regulatory Requirements: A Major Restraint for Market Growth
    Table 6 Emerging Markets Offer Significant Growth Opportunities
    Table 7 Stringent Regulatory Guidelines: A Major Challenge for Market Growth
    Table 8 Active Pharmaceutical Ingredients Market Size, By Type, 2014-2021 (USD Billion)
    Table 9 Indicative List of New Molecular Entities That Gained U.S. Fda Approval in 2016
    Table 10 Significant Patent Expiries, 2015
    Table 11 Innovative Active Pharmaceutical Ingredients Market Size, By Region, 2014-2021 (USD Billion)
    Table 12 North America: Innovative Active Pharmaceutical Ingredients Market Size, By Country, 2014-2021 (USD Billion)
    Table 13 Europe: Innovative Active Pharmaceutical Ingredients Market Size, By Country, 2014-2021 (USD Billion)
    Table 14 Asia: Innovative Active Pharmaceutical Ingredients Market Size, By Country, 2014-2021 (USD Billion)
    Table 15 Generic Active Pharmaceutical Ingredients Market, By Region, 2014-2021 (USD Billion)
    Table 16 North America: Generic Active Pharmaceutical Ingredients Market Size, By Country, 2014-2021 (USD Billion)
    Table 17 Europe: Generic Active Pharmaceutical Ingredients Market Size, By Country, 2014-2021 (USD Billion)
    Table 18 Asia: Generic Active Pharmaceutical Ingredients Market Size, By Country, 2014-2021 (USD Billion)
    Table 19 Active Pharmaceutical Ingredients Market Size, By Type of Manufacturer, 2014–2021 (USD Billion)
    Table 20 Captive API Manufacturers Market Size, By Region, 2014–2021 (USD Billion)
    Table 21 North America: Captive API Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
    Table 22 Europe: Captive API Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
    Table 23 Asia: Captive API Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
    Table 24 List of Significant Mergers and Acquisitions in the Cmo/Cdmo Industry
    Table 25 List of Significant Cmo/Cdmo Facility Expansions
    Table 26 Merchant API Manufacturers Market Size, By Region, 2014–2021 (USD Billion)
    Table 27 North America: Merchant API Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
    Table 28 Europe: Merchant API Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
    Table 29 Asia: Merchant API Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
    Table 30 Merchant API Manufacturers Market Size, By Type, 2014–2021 (USD Billion)
    Table 31 Innovative Merchant API Manufacturers Market Size, By Region, 2014–2021 (USD Billion)
    Table 32 North America: Innovative Merchant API Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
    Table 33 Europe: Innovative Merchant API Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
    Table 34 Asia: Innovative Merchant API Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
    Table 35 Generic Merchant API Manufacturers Market Size, By Region, 2014–2021 (USD Billion)
    Table 36 North America: Generic Merchant API Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
    Table 37 Europe: Generic Merchant API Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
    Table 38 Asia: Generic Merchant API Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
    Table 39 Merchant API Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 40 Merchant Synthetic API Manufacturers Market Size, By Region, 2014–2021 (USD Billion)
    Table 41 North America: Merchant Synthetic API Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
    Table 42 Europe: Merchant Synthetic API Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
    Table 43 Asia: Merchant Synthetic API Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
    Table 44 Merchant Biotech API Manufacturers Market Size, By Region, 2014–2021 (USD Billion)
    Table 45 North America: Merchant Biotech API Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
    Table 46 Europe: Merchant Biotech API Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
    Table 47 Asia: Merchant Biotech API Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
    Table 48 Active Pharmaceutical Ingredients Market Size, By Type of Synthesis, 2014–2021 (USD Billion)
    Table 49 Synthetic Active Pharmaceutical Ingredients Market Size, By Region, 2014–2021 (USD Billion)
    Table 50 North America: Synthetic Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
    Table 51 Europe: Synthetic Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
    Table 52 Asia: Synthetic Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
    Table 53 Synthetic Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 54 Innovative Synthetic Active Pharmaceutical Ingredients Market Size, By Region, 2014–2021 (USD Billion)
    Table 55 North America: Innovative Synthetic Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
    Table 56 Europe: Innovative Synthetic Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
    Table 57 Asia: Innovative Synthetic Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
    Table 58 Generic Synthetic Active Pharmaceutical Ingredients Market Size, By Region, 2014–2021 (USD Billion)
    Table 59 North America: Generic Synthetic Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
    Table 60 Europe: Generic Synthetic Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
    Table 61 Asia: Generic Synthetic Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
    Table 62 Top Selling Biologics (2015)
    Table 63 Biotech Active Pharmaceutical Ingredients Market Size, By Region, 2014–2021 (USD Billion)
    Table 64 North America: Biotech Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
    Table 65 Europe: Biotech Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
    Table 66 Asia: Biotech Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
    Table 67 Biotech Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 68 Innovative Biotech Active Pharmaceutical Ingredients Market Size, By Region, 2014–2021 (USD Billion)
    Table 69 North America: Innovative Biotech Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
    Table 70 Europe: Innovative Biotech Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
    Table 71 Asia: Innovative Biotech Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
    Table 72 Biosimilars Market Size, By Region, 2014–2021 (USD Billion)
    Table 73 North America: Biosimilars Market Size, By Country, 2014–2021 (USD Billion)
    Table 74 Europe: Biosimilars Market Size, By Country, 2014–2021 (USD Billion)
    Table 75 Asia: Biosimilars Market Size, By Country, 2014–2021 (USD Billion)
    Table 76 Biotech Active Pharmaceutical Ingredients Market Size, By Product, 2014–2021 (USD Billion)
    Table 77 Indicative List of Monoclonal Antibodies That Received Fda Approval in 2016
    Table 78 Monoclonal Antibodies Market Size, By Region, 2014–2021 (USD Billion)
    Table 79 North America: Monoclonal Antibodies Market Size, By Country, 2014–2021 (USD Billion)
    Table 80 Europe: Monoclonal Antibodies Market Size, By Country, 2014–2021 (USD Billion)
    Table 81 Asia: Monoclonal Antibodies Market Size, By Country, 2014–2021 (USD Billion)
    Table 82 Vaccines Market Size, By Region, 2014–2021 (USD Million)
    Table 83 North America: Vaccines Market Size, By Country, 2014–2021 (USD Million)
    Table 84 Europe: Vaccines Market Size, By Country, 2014–2021 (USD Million)
    Table 85 Asia: Vaccines Market Size, By Country, 2014–2021 (USD Million)
    Table 86 Hormones and Growth Factors Market Size, By Region, 2014–2021 (USD Billion)
    Table 87 North America: Hormones and Growth Factors Market Size, By Country, 2014–2021 (USD Billion)
    Table 88 Europe: Hormones and Growth Factors Market Size, By Country, 2014–2021 (USD Billion)
    Table 89 Asia: Hormones and Growth Factors Market Size, By Country, 2014–2021 (USD Billion)
    Table 90 Cytokines Market Size, By Region, 2014–2021 (USD Billion)
    Table 91 North America: Cytokines Market Size, By Country, 2014–2021 (USD Billion)
    Table 92 Europe: Cytokines Market Size, By Country, 2014–2021 (USD Million)
    Table 93 Asia: Cytokines Market Size, By Country, 2014–2021 (USD Million)
    Table 94 Fusion Proteins Market Size, By Region, 2014–2021 (USD Billion)
    Table 95 North America: Fusion Proteins Market Size, By Country, 2014–2021 (USD Billion)
    Table 96 Europe: Fusion Proteins Market Size, By Country, 2014–2021 (USD Million)
    Table 97 Asia: Fusion Proteins Market Size, By Country, 2014–2021 (USD Million)
    Table 98 Therapeutic Enzymes Market Size, By Region, 2014–2021 (USD Billion)
    Table 99 North America: Therapeutic Enzymes Market Size, By Country, 2014–2021 (USD Million)
    Table 100 Europe: Therapeutic Enzymes Market Size, By Country, 2014–2021 (USD Million)
    Table 101 Asia: Merchant Therapeutic Enzymes Market Size, By Country, 2014–2021 (USD Million)
    Table 102 Blood Factors Market Size, By Region, 2014–2021 (USD Million)
    Table 103 North America: Blood Factors Market Size, By Country, 2014–2021 (USD Million)
    Table 104 Europe: Blood Factors Market Size, By Country, 2014–2021 (USD Million)
    Table 105 Asia: Blood Factors Market Size, By Country, 2014–2021 (USD Million)
    Table 106 Biotech Active Pharmaceutical Ingredients Market Size, By Expression System, 2014–2021 (USD Billion)
    Table 107 Mammalian Expression Systems Market Size, By Region, 2014–2021 (USD Billion)
    Table 108 North America: Mammalian Expression Systems Market Size, By Country, 2014–2021 (USD Billion)
    Table 109 Europe: Mammalian Expression Systems Market Size, By Country, 2014–2021 (USD Billion)
    Table 110 Asia: Mammalian Expression Systems Market Size, By Country, 2014–2021 (USD Billion)
    Table 111 Microbial Expression Systems Market Size, By Region, 2014–2021 (USD Billion)
    Table 112 North America: Microbial Expression Systems Market Size, By Country, 2014–2021 (USD Billion)
    Table 113 Europe: Microbial Expression Systems Market Size, By Country, 2014–2021 (USD Billion)
    Table 114 Asia: Microbial Expression Systems Market Size, By Country, 2014–2021 (USD Billion)
    Table 115 Yeast Expression Systems Market Size, By Region, 2014–2021 (USD Billion)
    Table 116 North America: Yeast Expression Systems Market Size, By Country, 2014–2021 (USD Billion)
    Table 117 Europe: Yeast Expression Systems Market Size, By Country, 2014–2021 (USD Billion)
    Table 118 Asia: Yeast Expression Systems Market Size, By Country, 2014–2021 (USD Billion)
    Table 119 Plant Expression Systems Market Size, By Region, 2014–2021 (USD Billion)
    Table 120 North America: Plant Expression Systems Market Size, By Country, 2014–2021 (USD Billion)
    Table 121 Europe: Plant Expression Systems Market Size, By Country, 2014–2021 (USD Million)
    Table 122 Asia: Other Expression Systems Market Size, By Country, 2014–2021 (USD Million)
    Table 123 Insect Expression Systems Market Size, By Region, 2014–2021 (USD Billion)
    Table 124 North America: Insect Expression Systems Market Size, By Country, 2014–2021 (USD Billion)
    Table 125 Europe: Insect Expression Systems Market Size, By Country, 2014–2021 (USD Million)
    Table 126 Asia: Insect Expression Systems Market Size, By Country, 2014–2021 (USD Million)
    Table 127 Global Market Size, By Type of Drug, 2014–2021 (USD Billion)
    Table 128 Global Market Size for Prescription Drugs, By Region, 2014–2021 (USD Billion)
    Table 129 North America: Market Size for Prescription Drugs By Country, 2014–2021 (USD Billion)
    Table 130 Europe: Market Size for Prescription Drugs By Country, 2014–2021 (USD Billion)
    Table 131 Asia: Market Size for Prescription Drugs Country, 2014–2021 (USD Billion)
    Table 132 Prescription-To-Otc Switch List in the U.S.
    Table 133 Global Market Size for Over-The-Counter Drugs, By Region, 2014–2021 (USD Billion)
    Table 134 North America: Market Size for Over-The-Counter Drugs By Country, 2014–2021 (USD Billion)
    Table 135 Europe: Market Size for Over-The-Counter Drugs By Country, 2014–2021 (USD Billion)
    Table 136 Asia: Market Size for Over-The-Counter Drugs By Country, 2014–2021 (USD Billion)
    Table 137 Active Pharmaceutical Ingredients Market Size, By Potency, 2014-2021 (USD Billion)
    Table 138 Active Pharmaceutical Ingredients Market Size, By Therapeutic Application, 2014–2021 (USD Billion)
    Table 139 Cancer: Estimated Incidence, Mortality, and Prevalence (2012)
    Table 140 Active Pharmaceutical Ingredients Market Size for Oncology, By Region, 2014–2021 (USD Billion)
    Table 141 North America: Market Size for Oncology By Country, 2014–2021 (USD Billion)
    Table 142 Europe: Market Size for Oncology By Country, 2014–2021 (USD Billion)
    Table 143 Asia: Market Size for Oncology By Country, 2014–2021 (USD Billion)
    Table 144 Active Pharmaceutical Ingredients Market Size for Cvd, By Region, 2014–2021 (USD Billion)
    Table 145 North America: Active Pharmaceutical Ingredients Market Size for Cvd, By Country, 2014–2021 (USD Billion)
    Table 146 Europe: Market Size for Cvd, By Country 2014–2021 (USD Billion)
    Table 147 Asia: Active Pharmaceutical Ingredients Market Size for Cvd, By Country, 2014–2021 (USD Billion)
    Table 148 Active Pharmaceutical Ingredients Market Size for Diabetes, By Region, 2014–2021 (USD Billion)
    Table 149 North America: Market Size for Diabetes By Country, 2014–2021 (USD Billion)
    Table 150 Europe: Market Size for Diabetes By Country, 2014–2021 (USD Billion)
    Table 151 Asia: Market Size for Diabetes By Country, 2014–2021 (USD Billion)
    Table 152 Active Pharmaceutical Ingredients Market Size for Cns and Neurological Disorders, By Region, 2014–2021 (USD Billion)
    Table 153 North America: Market Size for Cns and Neurological Disorders By Country, 2014–2021 (USD Billion)
    Table 154 Europe: Market Size for Cns and Neurological Disorders By Country, 2014–2021 (USD Billion)
    Table 155 Asia: Market Size for Cns and Neurological Disorders By Country, 2014–2021 (USD Billion)
    Table 156 Active Pharmaceutical Ingredients Market Size for Endocrinology, By Region, 2014–2021 (USD Billion)
    Table 157 North America: Market Size for Endocrinology By Country, 2014–2021 (USD Billion)
    Table 158 Europe: Market Size for Endocrinology By Country, 2014–2021 (USD Billion)
    Table 159 Asia: Market Size for Endocrinology By Country, 2014–2021 (USD Billion)
    Table 160 Active Pharmaceutical Ingredients Market Size for Other Therapeutic Applications, By Region, 2014–2021 (USD Billion)
    Table 161 North America: Market Size for Other Therapeutic Applications, By Country, 2014–2021 (USD Billion)
    Table 162 Europe: Market Size for Other Therapeutic Applications By Country, 2014–2021 (USD Billion)
    Table 163 Asia: Market Size for Other Therapeutic Applications By Country, 2014–2021 (USD Billion)
    Table 164 Global Market Size By Region, 2014–2021 (USD Billion)
    Table 165 North America: Market Size By Country, 2014–2021 (USD Billion)
    Table 166 North America: Market Size By Type, 2014–2021 (USD Billion)
    Table 167 North America: Market Size By Type of Manufacturer, 2014–2021 (USD Billion)
    Table 168 North America: Merchant API Manufacturers Market Size, By Type, 2014–2021 (USD Billion)
    Table 169 North America: Merchant API Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 170 North America: Market Size By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 171 North America: Synthetic Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 172 North America: Biotech Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 173 North America: Biotech Active Pharmaceutical Ingredients Market Size, By Product, 2014–2021 (USD Billion)
    Table 174 North America: Biotech Active Pharmaceutical Ingredients Market Size, By Type of Expression System, 2014–2021 (USD Billion)
    Table 175 North America: Market Size By Type of Drug, 2014–2021 (USD Billion)
    Table 176 North America: Market Size By Therapeutic Application, 2014–2021 (USD Billion)
    Table 177 Recent Fda Approvals for NDA and ANDA
    Table 178 U.S.: Market Size By Type, 2014–2021 (USD Billion)
    Table 179 U.S.: Market Size By Type of Manufacturer, 2014–2021 (USD Billion)
    Table 180 U.S.: Merchant API Manufacturers Market Size, By Type, 2014–2021 (USD Billion)
    Table 181 U.S.: Merchant API Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 182 U.S.: Market Size By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 183 U.S.: Synthetic Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 184 U.S.: Biotech Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 185 U.S.: Biotech Active Pharmaceutical Ingredients Market Size, By Product, 2014–2021 (USD Billion)
    Table 186 U.S.: Biotech Active Pharmaceutical Ingredients Market Size, By Type of Expression System, 2014–2021 (USD Billion)
    Table 187 U.S.: Market Size By Type of Drug, 2014–2021 (USD Billion)
    Table 188 U.S.: Market Size By Therapeutic Application, 2014–2021 (USD Billion)
    Table 189 Canada: Market Size By Type, 2014–2021 (USD Billion)
    Table 190 Canada: Market Size By Type of Manufacturer, 2014–2021 (USD Billion)
    Table 191 Canada: Merchant API Manufacturers Market Size, By Type, 2014–2021 (USD Billion)
    Table 192 Canada: Merchant API Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 193 Canada: Market Size By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 194 Canada: Synthetic Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 195 Canada: Biotech Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 196 Canada: Biotech Active Pharmaceutical Ingredients Market Size, By Product, 2014–2021 (USD Million)
    Table 197 Canada: Biotech Active Pharmaceutical Ingredients Market Size, By Type of Expression System, 2014–2021 (USD Billion)
    Table 198 Canada: Market Size By Type of Drug, 2014–2021 (USD Billion)
    Table 199 Canada: Market Size By Therapeutic Application, 2014–2021 (USD Billion)
    Table 200 Europe: Market Size By Type, 2014–2021 (USD Billion)
    Table 201 Europe: Market Size By Type of Manufacturer, 2014–2021 (USD Billion)
    Table 202 Europe: Merchant API Manufacturers Market Size, By Type, 2014–2021 (USD Billion)
    Table 203 Europe: Merchant API Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 204 Europe: Market Size By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 205 Europe: Synthetic Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 206 Europe: Biotech Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 207 Europe: Biotech Active Pharmaceutical Ingredients Market Size, By Product, 2014–2021 (USD Billion)
    Table 208 Europe: Biotech Active Pharmaceutical Ingredients Market Size, By Type of Expression System, 2014–2021 (USD Billion)
    Table 209 Europe: Market Size By Type of Drug, 2014–2021 (USD Billion)
    Table 210 Europe: Market Size By Therapeutic Application, 2014–2021 (USD Billion)
    Table 211 Germany: Market Size By Type, 2014–2021 (USD Billion)
    Table 212 Germany: Market Size By Type of Manufacturer, 2014–2021 (USD Billion)
    Table 213 Germany: Merchant API Manufacturers Market Size, By Type, 2014–2021 (USD Billion)
    Table 214 Germany: Merchant API Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 215 Germany: Market Size By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 216 Germany: Synthetic Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 217 Germany: Biotech Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 218 Germany: Biotech Active Pharmaceutical Ingredients Market Size, By Product, 2014–2021 (USD Million)
    Table 219 Germany: Biotech Active Pharmaceutical Ingredients Market Size, By Type of Expression System, 2014–2021 (USD Billion)
    Table 220 Germany: Market Size By Type of Drug, 2014–2021 (USD Billion)
    Table 221 Germany: Market Size By Therapeutic Application, 2014–2021 (USD Billion)
    Table 222 France: Market Size By Type, 2014–2021 (USD Billion)
    Table 223 France: Market Size By Type of Manufacturer, 2014–2021 (USD Billion)
    Table 224 France: Merchant API Manufacturers Market Size, By Type, 2014–2021 (USD Billion)
    Table 225 France: Merchant API Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 226 France: Market Size By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 227 France: Synthetic Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 228 France: Biotech Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 229 France: Biotech Active Pharmaceutical Ingredients Market Size, By Product, 2014–2021 (USD Million)
    Table 230 France: Biotech Active Pharmaceutical Ingredients Market Size, By Type of Expression System, 2014–2021 (USD Billion)
    Table 231 France: Market Size By Type of Drug, 2014–2021 (USD Billion)
    Table 232 France: Market Size By Therapeutic Application, 2014–2021 (USD Billion)
    Table 233 U.K.: Market Size By Type, 2014–2021 (USD Billion)
    Table 234 U.K.: Market Size By Type of Manufacturer, 2014–2021 (USD Billion)
    Table 235 U.K.: Merchant API Manufacturers Market Size, By Type, 2014–2021 (USD Billion)
    Table 236 U.K.: Merchant API Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 237 U.K.: Market Size By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 238 U.K.: Synthetic Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 239 U.K.: Biotech Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 240 U.K.: Biotech Active Pharmaceutical Ingredients Market Size, By Product, 2014–2021 (USD Million)
    Table 241 U.K.: Biotech Active Pharmaceutical Ingredients Market Size, By Type of Expression System, 2014–2021 (USD Million)
    Table 242 U.K.: Market Size By Type of Drug, 2014–2021 (USD Billion)
    Table 243 U.K.: Market Size By Therapeutic Application, 2014–2021 (USD Billion)
    Table 244 Italy: Market Size By Type, 2014–2021 (USD Billion)
    Table 245 Italy: Market Size By Type of Manufacturer, 2014–2021 (USD Billion)
    Table 246 Italy: Merchant API Manufacturers Market Size, By Type, 2014–2021 (USD Billion)
    Table 247 Italy: Merchant API Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 248 Italian: Market Size By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 249 Italy: Synthetic Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 250 Italy: Biotech Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 251 Italy: Biotech Active Pharmaceutical Ingredients Market Size, By Product, 2014–2021 (USD Million)
    Table 252 Italy: Biotech Active Pharmaceutical Ingredients Market Size, By Type of Expression System, 2014–2021 (USD Million)
    Table 253 Italy: Market Size By Type of Drug, 2014–2021 (USD Billion)
    Table 254 Italy: Market Size By Therapeutic Application, 2014–2021 (USD Billion)
    Table 255 Spain: Market Size By Type, 2014–2021 (USD Billion)
    Table 256 Spain: Market Size By Type of Manufacturer, 2014–2021 (USD Billion)
    Table 257 Spain: Merchant API Manufacturers Market Size, By Type, 2014–2021 (USD Billion)
    Table 258 Spain: Merchant API Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 259 Spain: Market Size By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 260 Spain: Synthetic Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 261 Spain: Biotech Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 262 Spain: Biotech Active Pharmaceutical Ingredients Market Size, By Product, 2014–2021 (USD Million)
    Table 263 Spain: Biotech Active Pharmaceutical Ingredients Market Size, By Type of Expression System, 2014–2021 (USD Million)
    Table 264 Spain: Market Size By Type of Drug, 2014–2021 (USD Billion)
    Table 265 Spain: Market Size By Therapeutic Application, 2014–2021 (USD Billion)
    Table 266 RoE: Market Size By Type, 2014–2021 (USD Billion)
    Table 267 RoE: Market Size By Type of Manufacturer, 2014–2021 (USD Billion)
    Table 268 RoE: Merchant API Manufacturers Market Size, By Type, 2014–2021 (USD Billion)
    Table 269 RoE: Merchant API Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 270 RoE: Market Size By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 271 RoE: Synthetic Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 272 RoE: Biotech Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 273 RoE: Biotech Active Pharmaceutical Ingredients Market Size, By Product, 2014–2021 (USD Million)
    Table 274 RoE: Biotech Active Pharmaceutical Ingredients Market Size, By Type of Expression System, 2014–2021 (USD Million)
    Table 275 RoE: Market Size By Type of Drug, 2014–2021 (USD Billion)
    Table 276 RoE: Market Size By Therapeutic Application, 2014–2021 (USD Billion)
    Table 277 Asia: Market Size By Type, 2014–2021 (USD Billion)
    Table 278 Asia: Market Size By Type of Manufacturer, 2014–2021 (USD Billion)
    Table 279 Asia: Merchant API Manufacturers Market Size, By Type, 2014–2021 (USD Billion)
    Table 280 Asia: Merchant API Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 281 Asia: Market Size By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 282 Asia: Synthetic Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 283 Asia: Biotech Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 284 Asia: Biotech Active Pharmaceutical Ingredients Market Size, By Product, 2014–2021 (USD Million)
    Table 285 Asia: Biotech Active Pharmaceutical Ingredients Market Size, By Type of Expression System, 2014–2021 (USD Billion)
    Table 286 Asia: Market Size By Type of Drug, 2014–2021 (USD Billion)
    Table 287 Asia: Active Pharmaceutical Ingredients Market Size, By Therapeutic Application, 2014–2021 (USD Billion)
    Table 288 Japan: Market Size By Type, 2014–2021 (USD Billion)
    Table 289 Japan: Market Size By Type of Manufacturer, 2014–2021 (USD Billion)
    Table 290 Japan: Merchant API Manufacturers Market Size, By Type, 2014–2021 (USD Billion)
    Table 291 Japan: Merchant API Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 292 Japan: Market Size By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 293 Japan: Synthetic Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 294 Japan: Biotech Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 295 Japan: Biotech Active Pharmaceutical Ingredients Market Size, By Product, 2014–2021 (USD Million)
    Table 296 Japan: Biotech Active Pharmaceutical Ingredients Market Size, By Type of Expression System, 2014–2021 (USD Million)
    Table 297 Japan: Market Size By Type of Drug, 2014–2021 (USD Billion)
    Table 298 Japan: Market Size By Therapeutic Application, 2014–2021 (USD Billion)
    Table 299 China: Market Size By Type, 2014–2021 (USD Billion)
    Table 300 China: Market Size By Type of Manufacturer, 2014–2021 (USD Billion)
    Table 301 China: Merchant API Manufacturers Market Size, By Type, 2014–2021 (USD Billion)
    Table 302 China: Merchant API Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 303 China: Market Size By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 304 China: Synthetic Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 305 China: Biotech Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 306 China: Biotech Active Pharmaceutical Ingredients Market Size, By Product, 2014–2021 (USD Million)
    Table 307 China: Biotech Active Pharmaceutical Ingredients Market Size, By Type of Expression System, 2014–2021 (USD Million)
    Table 308 China: Market Size By Type of Drug, 2014–2021 (USD Billion)
    Table 309 China: Market Size By Therapeutic Application, 2014–2021 (USD Billion)
    Table 310 India: Market Size By Type, 2014–2021 (USD Billion)
    Table 311 Indian: Market Size By Type of Manufacturer, 2014–2021 (USD Billion)
    Table 312 India: Merchant API Manufacturers Market Size, By Type, 2014–2021 (USD Billion)
    Table 313 India: Merchant API Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 314 India: Market Size By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 315 India: Synthetic Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 316 India: Biotech Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 317 India: Biotech Active Pharmaceutical Ingredients Market Size, By Product, 2014–2021 (USD Million)
    Table 318 India: Biotech Active Pharmaceutical Ingredients Market Size, By Type of Expression System, 2014–2021 (USD Million)
    Table 319 India: Market Size By Type of Drug, 2014–2021 (USD Billion)
    Table 320 India: Market Size By Therapeutic Application, 2014–2021 (USD Billion)
    Table 321 South Korea: Market Size By Type, 2014–2021 (USD Billion)
    Table 322 South Korea: Market Size By Type of Manufacturer, 2014–2021 (USD Billion)
    Table 323 South Korea: Merchant API Manufacturers Market Size, By Type, 2014–2021 (USD Billion)
    Table 324 South Korea: Merchant API Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 325 South Korea: Market Size By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 326 South Korea: Synthetic Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 327 South Korea: Biotech Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 328 South Korea: Biotech Active Pharmaceutical Ingredients Market Size, By Product, 2014–2021 (USD Million)
    Table 329 South Korea: Biotech Active Pharmaceutical Ingredients Market Size, By Type of Expression System, 2014–2021 (USD Million)
    Table 330 South Korea: Market Size By Type of Drug, 2014–2021 (USD Billion)
    Table 331 South Korea: Market Size By Therapeutic Application, 2014–2021 (USD Billion)
    Table 332 RoA: Market Size By Type, 2014–2021 (USD Billion)
    Table 333 RoA: Market Size By Type of Manufacturer, 2014–2021 (USD Billion)
    Table 334 RoA: Merchant API Manufacturers Market Size, By Type, 2014–2021 (USD Billion)
    Table 335 RoA: Merchant API Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 336 RoA: Market Size By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 337 RoA: Synthetic Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 338 RoA: Biotech Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 339 RoA: Biotech Active Pharmaceutical Ingredients Market Size, By Product, 2014–2021 (USD Million)
    Table 340 RoA: Biotech Active Pharmaceutical Ingredients Market Size, By Type of Expression System, 2014–2021 (USD Million)
    Table 341 RoA: Market Size By Type of Drug, 2014–2021 (USD Billion)
    Table 342 RoA: Market Size By Therapeutic Application, 2014–2021 (USD Billion)
    Table 343 RoW: Market Size By Type, 2014–2021 (USD Billion)
    Table 344 RoW: Market Size By Type of Manufacturer, 2014–2021 (USD Billion)
    Table 345 RoW: Merchant API Manufacturers Market Size, By Type, 2014–2021 (USD Billion)
    Table 346 RoW: Merchant API Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 347 RoW: Market Size By Mode of Synthesis, 2014–2021 (USD Billion)
    Table 348 RoW: Synthetic Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 349 RoW: Biotech Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
    Table 350 RoW: Biotech Active Pharmaceutical Ingredients Market Size, By Product, 2014–2021 (USD Million)
    Table 351 RoW: Biotech Active Pharmaceutical Ingredients Market Size, By Type of Expression System, 2014–2021 (USD Billion)
    Table 352 RoW: Market Size By Type of Drug, 2014–2021 (USD Billion)
    Table 353 RoW: Market Size By Therapeutic Application, 2014–2021 (USD Billion)
    Table 354 Agreements, Collaborations, Partnerships, Joint Ventures, and Alliances (2013–2016)
    Table 355 Regulatory Approvals (2013-2016)
    Table 356 Mergers and Acquisitions (2013-2016)
    Table 357 Expansions (2013–2016)
    Table 358 Investments (2013–2016)
    Table 359 Exchange Rate (Utilized for the Conversion of Eur to USD)
    Table 360 Exchange Rate (Utilized for the Conversion of Gbp to USD)
    Table 361 Pfizer Inc. (U.S.)
    Table 362 Novartis International AG (Switzerland)
    Table 363 Sanofi (France)
    Table 364 Boehringer Ingelheim (Germany)
    Table 365 Bristol-Myers Squibb (U.S.)
    Table 366 Teva Pharmaceutical Industries Ltd. (Israel)
    Table 367 Glaxosmithkline PLC (U.K.)
    Table 368 Merck & Co., Inc. (U.S.)
    Table 369 Abbvie (U.S.)


    List of Figures (46 Figures)

    Figure 1 Research Design
    Figure 2 Market Size Estimation: Bottom-Up Approach
    Figure 3 Market Size Estimation: Top-Down Approach
    Figure 4 Breakdown of Primary Interviews: By Company Type, Designation, and Region
    Figure 5 Data Triangulation Methodology
    Figure 6 Active Pharmaceutical Ingredients Market Size, By Type, 2016 vs 2021
    Figure 7 Market Size By Type of Manufacturer, 2016 vs 2021
    Figure 8 Active Pharmaceutical Ingredients Market Size, By Type of Synthesis, 2016 vs 2021
    Figure 9 Biotech Active Pharmaceuticals Ingredients Market Size, By Product: Monoclonal Antibodies to Dominate the Market in 2016
    Figure 10 Active Pharmaceutical Ingredients Market Size, By Therapeutic Application, 2016 vs 2021
    Figure 11 Geographic Snapshot of the Active Pharmaceutical Ingredients Market
    Figure 12 Growing Importance of Generics, the Major Factor Driving the Growth of the Market
    Figure 13 Captive Manufacturers Segment to Account for the Largest Market Share in 2016
    Figure 14 Oncology Segment to Witness Highest Growth During the Forecast Period
    Figure 15 Monoclonal Antibodies Segment to Witness Highest Growth During the Forecast Period
    Figure 16 Over-The-Counter Drugs to Witness Highest Growth From 2016–2021
    Figure 17 Asia to Witness Highest Growth in the Active Pharmaceutical Ingredients Market During the Forecast Period
    Figure 18 Market Drivers, Restraints, Opportunities, and Challenges
    Figure 19 Innovative Segment to Dominate the Market in 2016
    Figure 20 Captive Manufacturers to Dominate the Market in 2016
    Figure 21 North America to Dominate the Market for Captive Manufacturers in 2016
    Figure 22 Synthetic Active Pharmaceutical Ingredients Segment to Dominate the Market in 2016
    Figure 23 North America to Dominate Synthetic Active Pharmaceutical Ingredients Market in 2016
    Figure 24 Prescription Drugs to Dominate the Active Pharmaceutical Ingredients Market, By Type of Drug, in 2016
    Figure 25 Low to Moderate Segment to Dominate the Active Pharmaceutical Ingredients Market, By Potency, in 2016
    Figure 26 Oncology Segment to Dominate the Active Pharmaceutical Ingredients Market, By Therapeutic Application
    Figure 27 North America to Dominate the Oncology Active Pharmaceutical Ingredients Market, By Region
    Figure 28 Asia to Witness Highest Growth During the Forecast Period (2016–2021)
    Figure 29 North America to Hold the Largest Share of the Global Active Pharmaceutical Ingredients Market (2016)
    Figure 30 European Active Pharmaceutical Ingredients Market Snapshot (2016)
    Figure 31 Asia: Market Snapshot (2016)
    Figure 32 RoW: Market Snapshot
    Figure 33 Key Developments in the Active Pharmaceutical Ingredients Market, 2013–2016
    Figure 34 Market Evolution Framework—Agreements, Partnerships, Collaborations, Joint Ventures, and Alliances Fueled Market Growth
    Figure 35 Battle for Market Share: Agreements, Partnerships, Collaborations, Joint Ventures, and Alliances Was the Key Strategy Adopted By Market Players (2013–2016)
    Figure 36 Geographic Mix of the Top 5 Players
    Figure 37 Pfizer, Inc.: Company Snapshot
    Figure 38 Novartis International AG: Company Snapshot
    Figure 39 Sanofi: Company Snapshot
    Figure 40 Boehringer Ingelheim: Company Snapshot
    Figure 41 Bristol-Myers Squibb: Company Snapshot
    Figure 42 Teva Pharmaceutical Industries Ltd.: Company Snapshot
    Figure 43 ELI Lilly and Company: Company Snapshot
    Figure 44 Glaxosmithkline PLC: Company Snapshot
    Figure 45 Merck & Co., Inc.: Company Snapshot
    Figure 46 Abbvie Inc.: Company Snapshot


    Request for detailed methodology, assumptions & how numbers were triangulated.

    Our USP is "Customised multi client reports"-so feel free to provide us specific interest in much greater detail..!!
    • Select all
    • News-Letters with latest Market insights
    • Information & discussion on the relevant new products and services
    • Information & discussion on Market insights and Market information
    • Information & discussion on our events and conferences
      • Select all
      • Email Phone Professional and social network (Linkedin, etc)
    Report Code
    PH 1262
    Published ON
    Jan, 2017
    Choose License Type
    BUY NOW
    • SHARE
    X
    Request Customization
    Speak to Analyst
    Speak to Analyst
    OR FACE-TO-FACE MEETING
    PERSONALIZE THIS RESEARCH
    • Triangulate with your Own Data
    • Get Data as per your Format and Definition
    • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
    • Any level of Personalization
    REQUEST A FREE CUSTOMIZATION
    LET US HELP YOU!
    • What are the Known and Unknown Adjacencies Impacting the Active Pharmaceutical Ingredients/API Market
    • What will your New Revenue Sources be?
    • Who will be your Top Customer; what will make them switch?
    • Defend your Market Share or Win Competitors
    • Get a Scorecard for Target Partners
    REQUEST A FREE WORKSHOP
    ADJACENT MARKETS
    ONLINE CHAT
    +1-888-600-6441
    • Call Us
    • +1-888-600-6441 (Corporate office hours)
    • +1-888-600-6441 (US/Can toll free)
    • +44-800-368-9399 (UK office hours)
    CONNECT WITH US
    ABOUT TRUST ONLINE
    © MarketsandMarkets Research Private Ltd. All rights reserved